StockNews.com Initiates Coverage on Can-Fite BioPharma (NYSE:CANF)

Investment analysts at StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research note issued on Thursday. The brokerage set a “sell” rating on the stock.

Separately, D. Boral Capital reissued a “buy” rating and set a $10.00 price target on shares of Can-Fite BioPharma in a report on Tuesday, April 15th.

Can-Fite BioPharma Trading Down 3.4 %

CANF opened at $1.13 on Thursday. Can-Fite BioPharma has a 1-year low of $1.13 and a 1-year high of $4.69. The firm’s 50 day simple moving average is $1.51 and its two-hundred day simple moving average is $1.73. The company has a market capitalization of $4.00 million, a PE ratio of -0.63 and a beta of 1.37.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Rhumbline Advisers boosted its stake in Can-Fite BioPharma Ltd. (NYSE:CANF) by 58.6% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 26,880 shares of the company’s stock after purchasing an additional 9,935 shares during the quarter. Rhumbline Advisers owned about 0.76% of Can-Fite BioPharma worth $44,000 as of its most recent SEC filing. Institutional investors and hedge funds own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.